EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%

被引：0
|
作者：
Rizvi, N. [1 ]
Lee, S. [2 ]
Curtis, P. [2 ]
Caldwell, W. [2 ]
Gao, B. [2 ]
Rietschel, P. [2 ]
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Anti-PD-1; cemiplimab; REGN2810;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.04-26
引用
收藏
页码：S931 / S932
页数：2
相关论文
共 50 条
  • [41] Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma
    Huang, Di
    Cui, Pengfei
    Huang, Ziwei
    Wu, Zhaozhen
    Tao, Haitao
    Zhang, Sujie
    Xiang, Rong
    Hu, Yi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (03) : 881 - 891
  • [42] Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma
    Di Huang
    Pengfei Cui
    Ziwei Huang
    Zhaozhen Wu
    Haitao Tao
    Sujie Zhang
    Rong Xiang
    Yi Hu
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 881 - 891
  • [43] ECONOMIC EVALUATION FOR THE UNITED STATES (US) OF THE OVERALL SURVIVAL ANALYSIS OF CEMIPLIMAB PLUS CHEMOTHERAPY TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH AT LEAST 50% PD-L1 POSITIVITY
    Alfayoumi, I
    VALUE IN HEALTH, 2024, 27 (06) : S64 - S64
  • [44] Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3
    Makharadze, Tamta
    Quek, Ruben G. W.
    Melkadze, Tamar
    Gogishvili, Miranda
    Ivanescu, Cristina
    Giorgadze, Davit
    Dvorkin, Mikhail
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Gessner, Christian
    Moreno-Jaime, Brizio
    Passalacqua, Rodolfo
    Konidaris, Gerasimos
    Rietschel, Petra
    Gullo, Giuseppe
    CANCER, 2023, 129 (14) : 2256 - 2265
  • [45] Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
    Yu, L.
    Xu, J.
    Qiao, R.
    Zhong, H.
    Han, B.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S391 - S392
  • [46] Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1
    Morabito, Alessandro
    DRUGS IN CONTEXT, 2024, 13
  • [47] THE COST EFFECTIVENESS ANALYSIS OF PD-1 AND PD-L1 AGENTS COMPARED WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Bae-Shaaw, Y. H.
    Hay, J. W.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [48] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
    Aguiar, P. N., Jr.
    Perry, L. A.
    Penny-Dimri, J.
    Babiker, H.
    Tadokoro, H.
    de Mello, R. A.
    Lopes, G. L., Jr.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2256 - 2263
  • [49] Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
    Boyer, M.
    Sendur, M. A. N.
    Rodriguez-Abreu, D.
    Park, K.
    Lee, D. H.
    Cicin, I.
    Yumuk, P. F.
    Orlandi, F.
    Leal, T.
    Molinier, O.
    Soparattanapaisam, N.
    Langleben, A.
    Califano, R.
    Medgyasszay, B.
    Hsia, T.
    Otterson, G.
    Xu, L.
    Piperdi, B.
    Samkari, A.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S61 - S62
  • [50] Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC)
    Leighl, N
    Laurie, S
    Knox, J
    Ellis, P
    Shepherd, F
    Burkes, R
    Pond, G
    Zwiebel, J
    Moore, M
    LUNG CANCER, 2005, 49 : S256 - S256
12345